Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA crite...
Published in: | Clinical Rheumatology |
---|---|
Main Authors: | , , , , |
Format: | Text |
Language: | English |
Published: |
Springer London
2017
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/ http://www.ncbi.nlm.nih.gov/pubmed/28190118 https://doi.org/10.1007/s10067-017-3570-4 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:5400786 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:5400786 2023-05-15T17:45:00+02:00 Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis Boman, Antonia Kokkonen, Heidi Ärlestig, Lisbeth Berglin, Ewa Rantapää-Dahlqvist, Solbritt 2017-02-11 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/ http://www.ncbi.nlm.nih.gov/pubmed/28190118 https://doi.org/10.1007/s10067-017-3570-4 en eng Springer London http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/ http://www.ncbi.nlm.nih.gov/pubmed/28190118 http://dx.doi.org/10.1007/s10067-017-3570-4 © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. CC-BY Original Article Text 2017 ftpubmed https://doi.org/10.1007/s10067-017-3570-4 2017-05-14T00:03:15Z The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and C-reactive protein were regularly recorded. Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed in plasma at baseline using ELISAs. Data on gene polymorphism for sclerostin and RANKL were extracted from Immunochip analysis. Sex- and age-matched controls (n = 71) were identified from the Medical Biobank of Northern Sweden. The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals. Sclerostin was significantly increased in female patients 0.59 (0.47–0.65) ng/mL compared with female controls 0.49 (0.4–0.65) ng/mL (p < 0.02). RANKL concentration was related to the Larsen score at baseline (p < 0.01), after 24 months (p < 0.001), and to radiological progression at 24 months (p < 0.001). Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. The concentration of RANKL was related to the Larsen score at baseline, at 24 months, and radiological progression at 24 months particularly in anti-CCP2-positive patients, while the concentration of sclerostin was unrelated to radiological findings. Text Northern Sweden PubMed Central (PMC) Clinical Rheumatology 36 5 1005 1012 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Original Article |
spellingShingle |
Original Article Boman, Antonia Kokkonen, Heidi Ärlestig, Lisbeth Berglin, Ewa Rantapää-Dahlqvist, Solbritt Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
topic_facet |
Original Article |
description |
The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and C-reactive protein were regularly recorded. Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed in plasma at baseline using ELISAs. Data on gene polymorphism for sclerostin and RANKL were extracted from Immunochip analysis. Sex- and age-matched controls (n = 71) were identified from the Medical Biobank of Northern Sweden. The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals. Sclerostin was significantly increased in female patients 0.59 (0.47–0.65) ng/mL compared with female controls 0.49 (0.4–0.65) ng/mL (p < 0.02). RANKL concentration was related to the Larsen score at baseline (p < 0.01), after 24 months (p < 0.001), and to radiological progression at 24 months (p < 0.001). Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. The concentration of RANKL was related to the Larsen score at baseline, at 24 months, and radiological progression at 24 months particularly in anti-CCP2-positive patients, while the concentration of sclerostin was unrelated to radiological findings. |
format |
Text |
author |
Boman, Antonia Kokkonen, Heidi Ärlestig, Lisbeth Berglin, Ewa Rantapää-Dahlqvist, Solbritt |
author_facet |
Boman, Antonia Kokkonen, Heidi Ärlestig, Lisbeth Berglin, Ewa Rantapää-Dahlqvist, Solbritt |
author_sort |
Boman, Antonia |
title |
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
title_short |
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
title_full |
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
title_fullStr |
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
title_full_unstemmed |
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
title_sort |
receptor activator of nuclear factor kappa-b ligand (rankl) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis |
publisher |
Springer London |
publishDate |
2017 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/ http://www.ncbi.nlm.nih.gov/pubmed/28190118 https://doi.org/10.1007/s10067-017-3570-4 |
genre |
Northern Sweden |
genre_facet |
Northern Sweden |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400786/ http://www.ncbi.nlm.nih.gov/pubmed/28190118 http://dx.doi.org/10.1007/s10067-017-3570-4 |
op_rights |
© The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.1007/s10067-017-3570-4 |
container_title |
Clinical Rheumatology |
container_volume |
36 |
container_issue |
5 |
container_start_page |
1005 |
op_container_end_page |
1012 |
_version_ |
1766147708483010560 |